Display options
Cite
Fashanu OE, Heckbert SR, Aguilar D, et al. Galectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) Study. Res Pract Thromb Haemost. 2017;1(2):223-230doi: 10.1002/rth2.12038.
Fashanu, O. E., Heckbert, S. R., Aguilar, D., Jensen, P. N., Ballantyne, C. M., Basu, S., Hoogeveen, R. C., deFilippi, C., Cushman, M., & Folsom, A. R. (2017). Galectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) Study. Research and practice in thrombosis and haemostasis, 1(2), 223-230. https://doi.org/10.1002/rth2.12038
Fashanu, Oluwaseun E, et al. "Galectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) Study." Research and practice in thrombosis and haemostasis vol. 1,2 (2017): 223-230. doi: https://doi.org/10.1002/rth2.12038
Fashanu OE, Heckbert SR, Aguilar D, Jensen PN, Ballantyne CM, Basu S, Hoogeveen RC, deFilippi C, Cushman M, Folsom AR. Galectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) Study. Res Pract Thromb Haemost. 2017 Oct;1(2):223-230. doi: 10.1002/rth2.12038. Epub 2017 Sep 04. PMID: 29152608; PMCID: PMC5685543.
Copy Download .nbib Format: NLM
Share it on

Res Pract Thromb Haemost. 2017 Oct;1(2):223-230. doi: 10.1002/rth2.12038. Epub 2017 Sep 04.

Galectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) Study.

Research and practice in thrombosis and haemostasis

Oluwaseun E Fashanu, Susan R Heckbert, David Aguilar, Paul N Jensen, Christie M Ballantyne, Saonli Basu, Ron C Hoogeveen, Christopher deFilippi, Mary Cushman, Aaron R Folsom

Affiliations

  1. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
  2. Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, WA, USA.
  3. Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  4. Cardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, WA, USA.
  5. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
  6. Academic Affairs, Inova Heart and Vascular Institute, Falls Church, Virginia, USA.
  7. Division of Hematology/Oncology, Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, USA.

PMID: 29152608 PMCID: PMC5685543 DOI: 10.1002/rth2.12038

Abstract

BACKGROUND: The inflammatory biomarker galectin-3 contributes to pathologic conditions such as heart failure and stimulates murine thrombogenesis. Its association with venous thromboembolism (VTE) has been sparsely studied.

OBJECTIVES: To assess the prospective association of plasma galectin-3 and the

METHODS: We measured plasma galectin-3 in 9,916 participants in the Atherosclerosis Risk in Communities (ARIC) study cohort in 1996 - 1998 and identified VTEs through 2013. Using Cox regression, we estimated the hazard ratio associating galectin-3 with incident VTE over a median of 13.9 years. Replication was sought in the Cardiovascular Health Study (CHS).

RESULTS: ARIC included 21.8% blacks and 56.2% females with mean baseline age of 62.7 years. The incidence rate of VTE (n=389 events) increased across quintiles of galectin-3, with hazard ratios (95% CI) of 1 (reference), 1.13 (0.80 - 1.61), 1.00 (0.70 - 1.43), 1.36 (0.96 - 1.91), and 1.55 (1.09 - 2.19) (p-trend = 0.005), adjusted for age, sex, race, body mass index, diabetes status, and renal function. Results did not replicate in the CHS (124 VTE), but meta-analysis of both studies yielded a pooled hazard ratio (95% CI) for 1 SD increment in log galectin-3 of 1.10 (1.00 - 1.22). In ARIC, the C allele of rs4644 in the

CONCLUSION: Galectin-3 levels were associated positively with VTE incidence.

Keywords: Galectin-3; Gene; Prospective; Thrombosis; Venous thromboembolism

References

  1. Am J Epidemiol. 1989 Apr;129(4):687-702 - PubMed
  2. Arch Intern Med. 2002 May 27;162(10):1182-9 - PubMed
  3. Thromb Haemost. 2009 Oct;102(4):615-9 - PubMed
  4. Heart. 2016 Jul 15;102(14):1134-41 - PubMed
  5. Stroke. 2013 Apr;44(4):961-7 - PubMed
  6. Physiol Genomics. 2011 Oct 20;43(20):1144-52 - PubMed
  7. Thromb Res. 2010 Jun;125(6):e269-74 - PubMed
  8. Cancer Lett. 2011 Dec 27;313(2):123-8 - PubMed
  9. Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1121-7 - PubMed
  10. PLoS One. 2013 Jul 12;8(7):e68095 - PubMed
  11. Ann Epidemiol. 1991 Feb;1(3):263-76 - PubMed
  12. Am J Med. 2004 Jul 1;117(1):19-25 - PubMed
  13. Ann Vasc Surg. 2011 Feb;25(2):229-39 - PubMed
  14. Nephrol Dial Transplant. 2010 Oct;25(10):3296-301 - PubMed
  15. Thromb Res. 2010 May;125(5):373-6 - PubMed
  16. J Am Coll Cardiol. 2010 Feb 2;55(5):441-50 - PubMed
  17. Am J Med. 2016 Mar;129(3):339.e19-26 - PubMed
  18. J Thromb Haemost. 2014 Oct;12(10):1580-90 - PubMed
  19. Clin Biochem. 2010 May;43(7-8):683-90 - PubMed
  20. Am J Kidney Dis. 2016 Jun;67(6):994-6 - PubMed
  21. JAMA. 2010 Dec 8;304(22):2494-502 - PubMed
  22. Crit Rev Oncol Hematol. 2016 Mar;99:272-85 - PubMed
  23. Ann Intern Med. 2009 May 5;150(9):604-12 - PubMed
  24. Nat Rev Dis Primers. 2015 May 07;1:15006 - PubMed
  25. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):433-40 - PubMed
  26. J Am Geriatr Soc. 2012 Jul;60(7):1201-7 - PubMed
  27. Am J Epidemiol. 2013 Oct 1;178(7):1076-84 - PubMed
  28. Blood. 2015 Mar 12;125(11):1813-21 - PubMed
  29. Am J Hum Genet. 2015 Apr 2;96(4):532-42 - PubMed
  30. Res Pract Thromb Haemost. 2017 Oct;1(2):223-230 - PubMed
  31. J Thromb Thrombolysis. 2016 Jan;41(1):3-14 - PubMed
  32. PLoS One. 2012;7(10):e47385 - PubMed
  33. J Am Coll Cardiol. 2012 Oct 2;60(14):1249-56 - PubMed

Publication Types

Grant support